We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Congressional supporters of a biosimilar approval pathway are pushing for it again with a new proposal that would allow follow-on products to be approved as interchangeable with brand biologics and provide 12 years of data exclusivity for innovator products.